Bioxcel therapeutics announces preliminary estimated unaudited second quarter net revenues from sales of igalmi™ (dexmedetomidine) sublingual film

Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch

BTAI Ratings Summary

BTAI Quant Ranking